Anti-human PDL1 monoclonal antibody and use thereof

A monoclonal antibody, antibody technology, applied in the direction of anti-animal/human immunoglobulin, application, anti-tumor drug, etc., can solve the problem of inducing immune response, no evidence of cancer patients, etc., to achieve the effect of novel sequence

Active Publication Date: 2021-07-23
BIOSION INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] To date, no satisfactory method has been demonstrated to induce potent immune responses in cancer patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-human PDL1 monoclonal antibody and use thereof
  • Anti-human PDL1 monoclonal antibody and use thereof
  • Anti-human PDL1 monoclonal antibody and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Obtaining specific anti-PDL1 mouse monoclonal antibody by fusion hybridoma technology

[0043] 1.1 Animal immunity

[0044] Mice were immunized according to the general method in the literature (E Harlow, D. Lane, Antibody: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998). 免疫原为重组人PDL1-Fc蛋白(公司自产,插入氨基酸序列为FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK)。 Recombinant human PDL1 with his-tagged protein (ACRO, Cat#PD1-H5229) was used as the detection antigen for determination of serum titer and hybridoma screening. Briefly, rem...

Embodiment 2

[0050] Example 2 In vitro analysis method for determining the functional activity of PDL1 monoclonal antibody

[0051] 2.1 Determination of antibody binding ability based on capture ELISA

[0052] Prepare goat anti-mouse IgG F(ab') in 1xPBS 2 The specific secondary antibody (Jackson ImmunoResearch Laboratories, Inc., Cat#115-005-072) was added to a 96-well microtiter plate at a final concentration of 2 μg / ml at 100 μl / well, and coated at 37° C. for 2 hours. After coating, the plate was washed once with PBS solution containing 0.05% Tween 20 (i.e. 1x PBST), then 200 μl / well of 1x PBST solution containing 5% skim milk powder was added and placed at 37°C for 2 hours to block. The plate was washed again, 100 μl / well of diluted antibody solution and PDL1-Benchmark (Tecentriq antibody, purchased from Roche) were added, incubated at 37° C. for 40 min, and then washed 4 times. Add biotin-labeled human PDL1 Fc protein solution (diluted 1:10000 in 1xPBST containing 2.5% skimmed milk p...

Embodiment 3

[0066] Example 3 DNA Cloning and Sequencing, Variable Region Sequencing of Anti-PDL1 Mouse Monoclonal Antibody

[0067] Total RNA was extracted from cultured mouse monoclonal cell lines using the FastPure Cell / Tissue Total RNA Isolation Kit (Vazyme, Cat#RC101). The process is briefly described as follows, centrifuged to collect 1.5x10 6Transfer the cells to a 1.5ml centrifuge tube and blot the supernatant dry. Add 500μl Buffer RL1 to the cell pellet and mix by pipetting. Transfer the treated cells to gDNA-Filter Columns (gDNA-Filter Columns have been placed in a collection tube), centrifuge at 13,000g for 2 minutes at room temperature, and save the supernatant in the collection tube. Add 1.6 times the volume of Buffer RL2 and mix gently. Transfer the mixture to RNAPureColumns, centrifuge at 13,000g for 1min at room temperature, and discard the waste. Add 500μl Buffer RW1 to RNAPure Columns, centrifuge at 13,000g for 1min at room temperature, and discard the waste. Add 700...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biology, relates to an anti-human PDL1 monoclonal antibody and use thereof, and also provides a coding nucleic acid molecule, an expression vector and a host cell of the antibody, and a method for expressing the antibody. The anti-human PDL1 monoclonal antibody can specifically recognize a human PDL1 monoclonal antibody. The antibody has a higher binding affinity with human PDL1 than that of an existing anti-human PDL1 monoclonal antibody, and has a novel sequence.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to a high-affinity and functional anti-human PDL1 monoclonal antibody or antibody fragment. The present invention also provides the encoding nucleic acid molecules of the antibody, expression vectors, host cells, and methods for expressing the antibody. Also provided are antibody immunoconjugates, bispecific molecules, chimeric antigen receptors, pharmaceutical compositions, and diagnostic and therapeutic methods comprising antibodies of the invention. Background technique [0002] Programmed death ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is a 40 kDa type I transmembrane protein. PDL1 is the surface glycoprotein ligand of PD-1, a key immune checkpoint receptor expressed by activated T cells and B cells, and mediates immune suppression. PDL1 has been implicated in suppression of immune system responses during chronic infection, pregna...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13A61P35/00
CPCC07K16/2827A61P35/00C07K2317/565C07K2317/56C07K2317/52C07K2317/92C07K2317/33C07K2317/76
Inventor 陈明久马志清彭则羽
Owner BIOSION INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap